30 completed. 30 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Completed 30 |
| Phase 2 | 8 | Completed 8 |
Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) zinc sulfate, Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Indiana University | 100 | 2025-02-10 | 2026-01-30 |
| L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity L-Arginine - Sickle Cell Disease | Phase 3 | Completed | Tanta University | 50 | 2022-07-25 | 2026-01-22 |
| Interest of Famotidine in Children With Sickle Cell Disease Famotidine 400 mg/50 mL - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2022-01-12 | 2025-10-08 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial L-Arginine Hydrochloride, Normal saline - Sickle Cell Disease | Phase 3 | Completed | Claudia R. Morris | 271 | 2021-06-21 | 2026-06-23 |
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE) Low-dose aspirin, Placebo - Intrauterine Growth Restriction, Preeclampsia | Phase 3 | Completed | University of Lagos, Nigeria | 476 | 2020-07-01 | 2025-01-09 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Hydroxyurea Optimization Through Precision Study Hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Completed | Lifespan | 104 | 2019-01-17 | 2025-06-18 |
| Vitamin D Supplementation in Children With Sickle Cell Disease Vitamin D bolus, Placebo - Sickle Cell Disease | Phase 3 | Completed | St. Justine's Hospital | 42 | 2018-11-30 | 2020-03-23 |
| A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Exa-cel - Sickle Cell Disease, Hematological Diseases | Phase 2 / Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 63 | 2018-11-27 | 2026-09-16 |
| Age of Blood in Sickle Cell Transfusion Transfusion - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | University of North Carolina, Chapel Hill | 26 | 2017-10-04 | 2024-11-19 |
| Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas Hydroxyurea - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Completed | Indiana University | 187 | 2017-07-26 | 2020-02-20 |
| Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa Moderate Dose Hydroxyurea, Low Dose Hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Completed | Vanderbilt University Medical Center | 120 | 2017-01-01 | 2022-01-19 |
| Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) voxelotor, Placebo - Sickle Cell Disease | Phase 3 | Completed | Pfizer | 449 | 2016-12-01 | 2023-07-27 |
| Oxygen Therapy and Pregnancy in Sickle Cell Disease oxygen therapy - Sickle Cell Disease | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 178 | 2016-10-05 | 2025-11-20 |
| Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II Hydroxyurea (Moderate Dose), Hydroxyurea (Low Dose) - Sickle Cell Disease, Stroke | Phase 3 | Completed | Vanderbilt University Medical Center | 440 | 2016-07-19 | 2020-08-03 |
| Evaluation of Repeat Administration of Purified Poloxamer 188 MST-188 - Sickle Cell Disease | Phase 3 | Completed | Mast Therapeutics, Inc. | 16 | 2015-06-01 | 2016-10-28 |
| Novel Use Of Hydroxyurea in an African Region With Malaria Hydroxyurea, Placebo - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Completed | Indiana University | 208 | 2014-09-01 | 2018-12-04 |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Saline, MST-188 - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 3 | Completed | Mast Therapeutics, Inc. | 388 | 2013-05-01 | 2016-10-28 |
| N-Acetylcysteine in Patients With Sickle Cell Disease N-Acetylcysteine, Placebo - Sickle Cell Disease | Phase 3 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 96 | 2013-04-01 | 2016-07-04 |
Showing 20 of 30. Sign in to see all of them.
Anemia, Sickle Cell (30) · Vaso-Occlusive Crises (5) · Pain (3) · Agnosia (2) · Anemia, Diamond-Blackfan (2) · Hematologic Diseases (2) · Malaria (2) · Stroke (2) · Thalassemia (2) · Acute Chest Syndrome (1) · Acute Lung Injury (1) · Anemia (1) · Fetal Growth Retardation (1) · Hemoglobinopathies (1) · Hemolysis (1)
Anemia, Hemolytic (30) · Anemia, Hemolytic, Congenital (30) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30) · Genetic Diseases, Inborn (30) · Hemic and Lymphatic Diseases (30) · Anemia (29) · Hemoglobinopathies (29) · Hematologic Diseases (28) · Pathological Conditions, Signs and Symptoms (6) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Anemia, Aplastic (2) · Anemia, Hypoplastic, Congenital (2) · Bone Marrow Diseases (2)
Hydroxyurea (6) · Alemtuzumab (2) · Arginine (2) · Morphine (2) · Zinc Sulfate (2) · fludarabine (2) · fludarabine phosphate (2) · Acetylcysteine (1) · Antilymphocyte Serum (1) · Aspirin (1) · Basigin (1) · Blood Transfusion (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Cardiovascular Agents (1)
Assistance Publique - Hôpitaux de Paris (4) · Indiana University (3) · Mast Therapeutics, Inc. (2) · Pfizer (2) · Vanderbilt University Medical Center (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Beni-Suef University (1) · Children's Healthcare of Atlanta (1) · Claudia R. Morris (1) · Hackensack Meridian Health (1) · Hospital de Clinicas de Porto Alegre (1) · Lifespan (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · National Institutes of Health Clinical Center (CC) (1)
United States (15) · France (7) · Belgium (4) · Canada (4) · Egypt (4) · Nigeria (4) · Turkey (Türkiye) (4) · United Kingdom (4) · Brazil (3) · Italy (3) · Lebanon (3) · Netherlands (3) · Oman (3) · Uganda (3) · Germany (2)
Michael R. DeBaun, MD, MPH (2) · Ahmed F Mahmoud Hussein, MS.c (1) · Angela Smith, MD (1) · Bart Biemond, MD, PhD (1) · Bosede B Afolabi, DM (Nott) (1) · Chandy C John, M.D. (1) · Chandy C John, MD (1) · Chandy C. John, M.D. (1) · Claudia Morris, MD (1) · David Brousseau, MD, MS (1) · Edwin L Parsley, D. O. (1) · Edwin L. Parsley, D.O. (1)
PMID 30952488, PMID 24443249, PMID 25520557, PMID 26232172, PMID 26431718, PMID 27339303, PMID 28337324, PMID 28606098, PMID 29051184, PMID 31135090, PMID 31199090, PMID 32462740, PMID 32579813, PMID 32616593, PMID 32873924, PMID 33246482, PMID 33283989, PMID 33476432, PMID 33838113, PMID 33877274, PMID 34175041, PMID 34971579, PMID 36123234, PMID 36383708, PMID 36860093, PMID 36975201, PMID 37587492, PMID 37722599, PMID 38661449, PMID 38775255, PMID 38866240, PMID 40526198, PMID 40608427, PMID 40765704, PMID 40857358, PMID 41026975, PMID 41190764, PMID 41312340, PMID 41713441, PMID 42616536, PMID 42616542
K23HL136787 (1), R01NS094041 (1), UG3HL148560 (1)